TearClear is a Boston, MA-based ophthalmic pharmaceutical company advancing multiple clinical programs, with two lead candidates targeting glaucoma. The company plans to use new funding to advance those clinical programs and pursue future indications. TearClear is led by Chief Executive Officer Robert Dempsey. It recently appointed Stuart Raetzman, formerly CEO of Galderma, to its board of directors. The announcement emphasizes progress across its glaucoma candidates as the near-term clinical focus. TearClear is an Orange County, California-based eye health technology company developing a delivery system to enable preservative-free topical ophthalmic drugs from existing preserved, multi-dose systems. The company's technology targets drugs used to treat chronic ophthalmic diseases where benzalkonium chloride (BAK) is commonly used to assure sterility. TearClear aims to address the global market for ophthalmologic drugs, including treatments for glaucoma, over-the-counter dry eye, and allergic conjunctivitis. Leadership includes CEO Kevin Hershfield, Chairman Rick Heinick, Chief Science & Technology Officer Richard D’Souza, Head of Clinical Development Howard Golub, and inventor Anuj Chauhan. The company raised $4.5M in Series A financing and plans to use the proceeds to advance development of its delivery system for preservative-free ophthalmic drugs. William Link, PhD, with executive and investment expertise in ophthalmology, was appointed to the board of directors as part of the financing.

Total raised

$27M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2020